A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. (2020)

First Author: Sharpley AL
Attributed to:  Clinical Psychopharmacology of Depression funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00213-020-05654-1

PubMed Identifier: 32909076

Publication URI: http://europepmc.org/abstract/MED/32909076

Type: Journal Article/Review

Volume: 237

Parent Publication: Psychopharmacology

Issue: 12

ISSN: 0033-3158